Chimerix (CMRX) is Downgraded by JP Morgan to Neutral according to the research report released to the investors. The Brokerage Firm has Lowered the Price Target of the company shares to $15 from a previous price target of $65 . Earlier the firm had a rating of Overweight on the company shares. The shares recommendation by the Brokerage Firm was released on Dec-29-2015.
The company shares have dropped 8.18% in the past 52 Weeks. On August 5, 2015 The shares registered one year high of $58.04 and one year low was seen on October 20, 2015 at $33.02. The 50-day moving average is $37.97 and the 200 day moving average is recorded at $43.76. S&P 500 has rallied 1.33% during the last 52-weeks.
Chimerix, Inc. (NASDAQ:CMRX) has lost 0.95% during the past week and dropped 15.15% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 3.61%. Chimerix, Inc. (NASDAQ:CMRX) has underperformed the index by 13.95% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
During the last several months other analysts have commented on the company rating. UBS initiates coverage on Chimerix, Inc. (NASDAQ:CMRX) In a research note issued to the investors, the brokerage major announces a price-target of $55 per share.The shares have been rated Buy. The rating by the firm was issued on December 17, 2015.
Shares of Chimerix, Inc. (NASDAQ:CMRX) ended Thursday session in red amid volatile trading. The shares closed down 0.21 points or 0.59% at $35.57 with 156,097 shares getting traded. Post opening the session at $35.45, the shares hit an intraday low of $35.42 and an intraday high of $35.815 and the price vacillated in this range throughout the day. The company has a market cap of $1,641 million and the number of outstanding shares has been calculated to be 46,146,101 shares. The 52-week high of Chimerix, Inc. (NASDAQ:CMRX) is $58.04 and the 52-week low is $33.02.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Demski Martha J, director of Chimerix Inc, unloaded 1,126 shares at an average price of $40.42 on November 2, 2015. The total amount of the transaction was worth $45,513, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Chimerix, Inc. (NASDAQ:CMRX) shares are expected to touch $60.4 in the short term. This short term price target has been shared by 10 analysts. However, the standard deviation of short term price estimate has been valued at 7.46. The target price could hit $73 on the higher end and $50 on the lower end.
Chimerix, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Its lipid technology has given rise to two clinical-stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced antiviral activity and safety in convenient, orally administered dosing regimens. CMX001 is an orally administered drug that utilizes its lipid technology to deliver intracellular concentrations of a potent antiviral compound, cidofovir-diphosphate (CDV-PP). CMX157, Its second clinical stage compound, is an oral nucleotide compound in Phase 1 development for the treatment of human immunodeficiency virus (HIV) infection.